Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Bell Direct SMSF online portal demo

Bell Direct
October 7, 2019

Livewire Markets & Bell Direct partnership

Arnie Selvarajah
September 20, 2019

Platinum Global Fund

Bell Direct
August 23, 2019

Bell Global Emerging Companies Fund

Bell Direct
August 23, 2019

June Market Overview

Julia Lee
July 11, 2019

May Market Overview

Julia Lee
May 31, 2019

April Market Overview

Julia Lee
April 29, 2019

Investing in ETFs

Bell Direct
April 17, 2019

March Market Overview

Julia Lee
March 28, 2019